PANKU-Breast01 met its primary endpoint in unresectable locally advanced, recurrent or metastatic HR+/HER2- breast cancer after at least one prior chemotherapy, with median progression-free survival of 8.2 months for izalontamab brengitecan versus 4.0 months for chemotherapy (HR: 0.41; 95% CI: 0.33-0.53, p<0.0001). The signal is supported by earlier single-arm phase 1b data in heavily pretreated disease where 69.8% had 3 or more prior lines, reporting confirmed response rates of 46.3% in HER2-positive, 37.3% in HR+/HER2- and 34.8% in triple-negative groups. [1] Context comes only from mechanistically distinct Phase 3 RCT peers including ribociclib in MONALEESA-2 and MONALEESA-7, abemaciclib in MONARCH3 and palbociclib in PALOMA-2, plus randomized Phase 2 Right Choice of ribociclib plus endocrine therapy versus chemotherapy, none sharing the EGFRxHER3 bispecific antibody-drug conjugate mechanism. [2] Payer expectations remain anchored in endocrine-based first-line care with CDK4/6 inhibitors and category 1 bone-modifying agents with 12-week bisphosphonate dosing where indicated, positioning iza-bren in later-line endocrine-refractory use. [2] Regulatory interpretation will require mature overall survival and full safety characterization, consistent with 26.4-month, 90.1-month and 8.1-year follow-up reported for those CDK4/6 programs. No closely comparable precedent exists for this mechanism and post-chemotherapy context, and absence of overall survival, response and grade 3 or greater toxicity leaves the pivotal benefit-risk unproven. [3]
PANKU-Breast01 Phase 3 RCT met PFS primary endpoint, but OS, ORR and safety absent versus long follow-up in MONALEESA, MONARCH3 and PALOMA programs.
| Indication | HR+/HER2- breast cancer |
| Drug | izalontamab brengitecan |
| Mechanism of Action | dual-targeting EGFRxHER3 bispecific antibody-drug conjugate |
| Company | SystImmune |
| Trial Phase | Phase 3 |
| Trial Acronym | PANKU-Breast01 |
| NCT ID | NCT06343948 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Patient Population | Patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- breast cancer who failed at least one prior line of chemotherapy |
| Primary Endpoint | Progression-Free Survival (PFS) |
| Median PFS | 8.2 months (iza-bren) vs. 4.0 months (chemotherapy) |
| Hazard Ratio (HR) | 0.41 |
| 95% Confidence Interval (CI) | 0.33-0.53 |
| p-value | <0.0001 |
| Objective Response Rate (cORR) | 40.5% (iza-bren) vs. 20.2% (chemotherapy) |
| Median Duration of Response (mDOR) | 6.9 months (iza-bren) vs. 4.2 months (chemotherapy) |
| Follow-up Duration | 15.2 months |
| Conference | European Society for Medical Oncology (ESMO) 2026 Annual Congress |
Iza-Bren Demonstrates Significant PFS Benefit in Advanced Breast Cancer
SystImmune and Bristol Myers Squibb announced positive results from the Phase 3 PANKU-Breast01 study of izalontamab brengitecan (iza-bren) in patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- breast cancer who had failed at least one prior line of chemotherapy. The investigational dual-targeting EGFRxHER3 bispecific antibody-drug conjugate reduced the risk of disease progression or death, the primary endpoint, by 59% compared to chemotherapy. Median progression-free survival (PFS) was 8.2 months for iza-bren versus 4.0 months for chemotherapy (HR: 0.41; 95% CI: 0.33-0.53, p<0.0001). These late-breaking results will be presented at ESMO 2026, highlighting iza-bren's potential as a new treatment option.
- The PANKU-Breast01 study demonstrated izalontamab brengitecan's superior efficacy, reducing the risk of disease progression or death by 59% (HR: 0.41; 95% CI: 0.33-0.53, p<0.0001) compared to chemotherapy. Patients treated with iza-bren achieved a median progression-free survival of 8.2 months, more than double the 4.0 months observed in the chemotherapy arm, as assessed by Blinded Independent Central Review after a median follow-up of 15.2 months.
- Beyond the primary endpoint, iza-bren also showed favorable results in key secondary endpoints. The confirmed objective response rate (cORR) was 40.5% for iza-bren versus 20.2% for chemotherapy, with a median duration of response (mDOR) of 6.9 months compared to 4.2 months. The study enrolled patients with advanced HR+/HER2- breast cancer who had progressed after at least one prior line of chemotherapy, addressing a population with limited treatment options.
- Izalontamab brengitecan exhibited a manageable safety profile, with no new safety signals identified. Grade ≥3 treatment-related adverse events were primarily hematologic and manageable with supportive care, leading to discontinuation in only 1.6% of patients. The drug's unique dual-targeting EGFRxHER3 mechanism positions it as a potentially first-in-class ADC, with clinical benefit demonstrated across five distinct tumor types, including a Breakthrough Therapy Designation for EGFR-mutated NSCLC.
Addressing Unmet Needs in Advanced HR+/HER2- Breast Cancer
Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate compared with endocrine therapy alone, but tolerability, adherence and biomarker-guided selection remain limiting factors.
Endocrine resistance and persistent recurrence risk: Resistance to endocrine therapy (ET) is common in patients with HR+ advanced breast cancer (ABC). The 5-year probability of BC recurrence or death was 17.2% (95% credible interval: 14.6%-20.3%) in node-positive patients receiving adjuvant endocrine therapy, with approximately 1 in 6 women experiencing recurrence or death within 5-years of initiating treatment.
Uncertainty after prior CDK4/6 inhibitor failure and lack of resistance biomarkers: There is uncertainty regarding the usefulness of CDK4/6-inhibitor-based therapy for HR+, HER2-, metastatic breast cancer (MBC), when CDK4/6 inhibitor treatment had previously failed, and a biomarker for abemaciclib resistance has not been identified. Hyperactivation of the phosphoinositide 3-kinase (PI3K) signaling pathway is implicated in resistance to ET, with activating mutations or amplification of PIK3CA as the most frequent mechanism, and patients with PIK3CA mutations respond best to PI3Kα-isoform inhibition.
Tolerability burden and treatment modifications: Diarrhoea, infections and neutropenia were the most common adverse events with abemaciclib plus endocrine therapy, and neutropenia was the most frequent grade 3-4 AE with palbociclib combined with endocrine therapy, with no febrile neutropenia events in a 46-patient cohort. With alpelisib + fulvestrant, hyperglycemia, rash, and diarrhea occurred at 66.7%, 45.5%, and 72.7%, respectively, required hospitalizations and pharmacological treatment, and 27% of patients discontinued treatment due to adverse effects. Ribociclib showed the highest risk for all-grade (AG) and grade ≥ 3 (G3+) alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) elevation.
Adherence challenge with oral targeted agents: Adherence presents a challenge to disease management, particularly with new oral drugs, with factors influencing adherence including maintaining patients' satisfaction and early detection/management of side effects. The prerequisite for prolonged progression-free survival and overall survival is adherence to therapy over the entire course of treatment.
Efficacy-effectiveness gap in real-world and heavily pretreated populations: In real-world practice, median PFS was 10.0 months (95% confidence interval (CI) 4.9-15.1) with palbociclib, while patients who did not meet PALOMA-3 eligibility criteria (n = 16) showed a lower median PFS of 5.5 months (95% CI 4.7-6.4). Outcomes of alpelisib + fulvestrant were worse in the real-world salvage setting as compared to the front-line setting, with 49% discontinuing due to progression of disease. Challenges facing implementation of routine PIK3CA mutation testing must be addressed so robust and reproducible genotyping can be obtained with liquid and tumor biopsies in a timely and cost-effective manner.
PANKU-Breast01: Design and Pivotal Efficacy in HR+/HER2- BC
Key trials in HR-positive/HER2-negative advanced breast cancer span first-line endocrine-sensitive CDK4/6 inhibitor combinations to endocrine-resistant PIK3CA-mutated and previously treated settings. Designs include randomized double-blind phase II and phase 3 studies, a randomized phase II study with observational extended follow-up, and a phase 2 multicentre open-label non-comparative study.
| Trial | Design and Population | Treatment Arms | Primary Endpoint(s) and Key Results |
|---|---|---|---|
| GEICAM/2014-12 (FLIPPER) | Randomized (1:1), double-blind, phase II study in postmenopausal women with HR-positive, HER2-negative ABC with de novo metastatic disease or those who relapsed after >12 months of adjuvant endocrine therapy; 189 patients randomized | Palbociclib/fulvestrant (n = 94) vs placebo/fulvestrant (n = 95) | Primary objective was one-year progression-free survival (PFS-1y) rate; PFS-1y rates were 83.5% and 71.9% (HR 0.55, 80% CI 0.36-0.83, P = 0.064); median PFS were 31.8 and 22.0 months (aHR 0.48, 80% CI 0.37-0.64, P = 0.001) |
| INAVO120 | Randomized, double-blind, placebo-controlled trial in 325 patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or MBC | Inavolisib (n = 161) vs placebo (n = 164) in combination with palbociclib and fulvestrant | Primary end point of progression-free survival (PFS) by investigator assessment; median PFS of 15.0 months for inavolisib + palbociclib + fulvestrant versus 7.3 months for placebo + palbociclib + fulvestrant (hazard ratio [HR], 0.43 [95% CI, 0.32 to 0.59]; P < .0001) |
| PARSIFAL and PARSIFAL-LONG | Randomized phase II study with international, multicenter, observational extended follow-up; postmenopausal patients with endocrine-sensitive, HR-positive/HER2-negative ABC; 419 of 486 (86.2%) patients from PARSIFAL included; median follow-up was 7.3 years | Palbociclib with fulvestrant vs palbociclib with letrozole | Primary objective evaluated updated OS; secondary objectives included updated investigator-assessed PFS; median OS for overall population was 61.8 months (95% CI 56.5-68.4 months); median PFS was 32.6 months (95% CI 27.5-38.1 months); no differences between fulvestrant and letrozole for OS (hazard ratio 1.01, 95% CI, 0.80-1.28, P = 0.927) or PFS (hazard ratio 1.06, 95% CI, 0.85-1.31, P = 0.612) |
| MONARCH 2 premenopausal subgroup | Premenopausal subgroup of MONARCH 2 trial in HR-positive, HER2-negative ABC patients who were endocrine therapy (ET) resistant; 114 premenopausal patients | Abemaciclib plus fulvestrant (n = 72) vs placebo plus fulvestrant (n = 42) | Primary objective was investigator-assessed PFS; median PFS was not reached vs 10.52 months (HR 0.415; 95% CI 0.246-0.698) at cutoff (February 14, 2017); median PFS was 28.6 months vs 10.26 months (HR 0.477; 95% CI 0.302-0.755) at OS interim cutoff (20-June-2019) |
| TROPION-Breast01 (NCT05104866) | Phase III study; patients with inoperable/metastatic HR-positive/HER2-negative breast cancer, who had disease progression on endocrine therapy and had received one to two prior lines of chemotherapy; randomly assigned in a 1:1 ratio | Datopotamab deruxtecan (Dato-DXd) (6 mg/kg every 3 weeks) vs investigator's choice of chemotherapy (ICC) (eribulin/capecitabine/vinorelbine/gemcitabine) | Dual primary endpoints were PFS by BICR and OS; OS did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445); median follow-up was 22.8 months |
| MONALEESA-2 (NCT01958021) | Randomized, placebo-controlled, phase 3 trial in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease | Ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day) vs placebo plus letrozole | Primary end point was investigator-assessed progression-free survival; median PFS was 25.3 months [95% CI 23.0-30.3] vs 16.0 months (95% CI 13.4-18.2) (hazard ratio 0.568; 95% CI 0.457-0.704; log-rank P = 9.63 × 10-8); ORR was 42.5% versus 28.7% |
| BYLieve cohort A (NCT03056755) | Phase 2, multicentre, open-label, non-comparative study in patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as immediate previous treatment; 127 patients enrolled, 119 with centrally confirmed PIK3CA mutation | Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1 | Primary endpoint was proportion alive without disease progression at 6 months; 64 (53.8%; 95% CI 44.4-63.0) of 119 patients were alive without disease progression at 6 months; median follow-up was 21.8 months |
Iza-Bren's Dual-Targeting Potential Across Multiple Tumor Types
Izalontamab brengitecan (iza-bren; BL-B01D1) is a first-in-class EGFR-HER3 bispecific antibody-drug conjugate evaluated in multiple solid tumors beyond HR+/HER2- breast cancer. Registrational Phase III trials in nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and triple-negative breast cancer met primary endpoints, with NMPA approvals in nasopharyngeal carcinoma and esophageal squamous cell carcinoma in June 2026 and July 2026.
Extensive-stage small cell lung cancer (ES-SCLC): open-label, multicenter, dose-expansion phase Ib study (NCT05194982) of iza-bren 2.5 mg/kg on days 1 and 8 of each 3-week cycle in patients progressed on prior systemic therapies, with a phase III randomized controlled trial of iza-bren compared with topotecan (NCT06500026) ongoing
EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR TKI progression: pooled phase 1a/1b dose-escalation/expansion trial (BL-B01D1-101; NCT05194982) and phase 2 multicohort trial (BL-B01D1-203; NCT05880706) using recommended phase 2 dose of 2.5 mg/kg on days 1 and 8 every 3 weeks
NSCLC with actionable genomic alterations outside classical EGFR mutations: phase Ib study in EGFR exon20ins/nonclassical mutations, HER2 mutation, KRAS/BRAF/MET mutation, and ALK/ROS1/RET/NTRK fusion cohorts using iza-bren 2.5 mg/kg on days 1 and 8 of each 3-week cycle
Recurrent or metastatic nasopharyngeal carcinoma: multicentre, randomised, open-label, phase 3 study (NCT06118333) at 55 hospitals in China randomizing (1:1) to iza-bren 2·5 mg/kg intravenously on days 1 and 8 of each 3-week cycle or chemotherapy in patients progressed after at least two lines of systemic chemotherapy including at least one platinum-containing regimen and PD-1 or PD-L1 inhibitors
Recurrent or metastatic esophageal squamous cell carcinoma and triple-negative breast cancer: registrational Phase III trials meeting primary endpoints, supporting NMPA approval for adult patients with recurrent or metastatic esophageal squamous cell carcinoma who have experienced disease progression after prior therapy with a PD-1/PD-L1 inhibitor in combination with platinum-containing chemotherapy, and NMPA approval for adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapy
A New Horizon for HR+/HER2- Breast Cancer Treatment
The recent announcement of positive Phase 3 results for izalontamab brengitecan (iza-bren) in HR+/HER2- metastatic breast cancer represents a significant stride forward for patients facing limited options after prior chemotherapy. This first-in-class EGFRxHER3 bispecific antibody-drug conjugate has demonstrated a remarkable 59% reduction in the risk of progression or death, translating to a median progression-free survival of 8.2 months compared to 4.0 months with chemotherapy. This robust efficacy signal, building on promising earlier-phase data, positions iza-bren as a potential new cornerstone therapy in this challenging setting.
The strategic implications for SystImmune and Bristol Myers Squibb are substantial. The successful validation of a novel bispecific ADC targeting EGFR and HER3 could unlock a new therapeutic paradigm, not only for breast cancer but potentially for other solid tumors where these pathways are implicated. This could provide a significant competitive edge, allowing the companies to carve out a distinct market position in a crowded oncology landscape.
However, the path forward is not without considerations. While efficacy is compelling, the safety profile observed in earlier studies warrants close attention.
A high incidence of treatment-related adverse events, particularly hematologic toxicities such as neutropenia and anemia, was noted, requiring proactive management.
The occurrence of treatment-related deaths, including febrile neutropenia and intracranial hemorrhage, underscores the need for careful patient selection and monitoring in real-world clinical practice.
The full safety and efficacy data, anticipated at ESMO 2026, will be critical for a comprehensive understanding of iza-bren's benefit-risk profile. Should these detailed data reinforce the strong efficacy while demonstrating manageable toxicity, iza-bren could redefine treatment expectations for patients with advanced HR+/HER2- breast cancer, offering a much-needed new therapeutic avenue.
Frequently Asked Questions
References
- [1] Bui TBV, Burgers DM et al.. Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy. Breast cancer : basic and clinical research. 2019. 30675102
- [2] Yamamura J, Masuda N et al.. Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. Chemotherapy. 2017. 28605730
- [3] Meegdes M, Geurts SME et al.. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. The Lancet regional health. Europe. 2023 Mar. 36895447
- [4] [Expert Consensus on Clinical Application of Izalontamab Brengitecan (2026 Edition)]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2026 Aug 31. 42669450
- [5] Berdunov V, Cuyún-Carter G et al.. Cost-Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer. Oncology and therapy. 2025 Mar. 39576592
- [6] Pawloski KR, Barrio AV. Breast surgery after neoadjuvant systemic therapy. Translational breast cancer research : a journal focusing on translational research in breast cancer. 2024. 38751679
- [7] Muğlu H, Helvacı K et al.. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey. Cancers. 2025 May 7. 40361516
- [8] Mao Y, Lv M et al.. Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review. Frontiers in oncology. 2022. 36698413
- [9] Neven P, Rugo HS et al.. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast cancer research : BCR. 2021 Aug 23. 34425869
- [10] Kümmel S, Paepke S et al.. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European journal of cancer (Oxford, England : 1990). 2017 Oct. 28768217
- [11] Kimbung S, Markholm I et al.. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International journal of cancer. 2018 Feb 1. 28940389
- [12] Müller C, Kiver V et al.. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. Breast care (Basel, Switzerland). 2023 Feb. 36876172
- [13] Hong SD, Wang YS et al.. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2026 Jun. 41611210
- [14] Llombart-Cussac A, Pérez-García JM et al.. Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO open. 2025 Jul. 40532361
- [15] Crescioli S, Kaplon H et al.. Antibodies to watch in 2026. mAbs. 2026 Dec. 41560619
- [16] Boyle F, Beith J et al.. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia-Pacific journal of clinical oncology. 2018 Oct. 30288930
- [17] Pistilli B, Jhaveri K et al.. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2026 May. 41448362
- [18] Shi ZQ, Qiu PF et al.. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. The breast journal. 2019 Nov. 31332886
- [19] Masuda N, Lee SJ et al.. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England journal of medicine. 2017 Jun 1. 28564564
- [20] Hortobagyi GN, Stemmer SM et al.. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England journal of medicine. 2016 Nov 3. 27717303
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
